share_log

Invivyd Class Action: Levi & Korsinsky Reminds Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of April 3, 2023 - IVVD

Invivyd Class Action: Levi & Korsinsky Reminds Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of April 3, 2023 - IVVD

Invivyd 集體訴訟:列維和科爾辛斯基提醒 Invivyd,Inc. F/K/A 阿達吉奧治療藥物公司投資人正在處理中的集體訴訟,主要原告截止日期為 2023 年 4 月 3 日-IVVD
newsfile ·  2023/02/08 14:14

New York, New York--(Newsfile Corp. - February 8, 2023) - Levi & Korsinsky, LLP notifies investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd" or the "Company") (NASDAQ: IVVD) of a class action securities lawsuit.

紐約,紐約-(Newsfile Corp.-2023年2月8日)-Levi&Korsinsky,LLP通知投資者Invivyd,Inc.f/k/a Adagio治療公司(“因維達”或“公司”)(納斯達克:IVVD)的集體證券訴訟。

The lawsuit on behalf of Invivyd investors has been commenced in the the United States District Court for the District of Massachusetts. This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive. Follow the link below to get more information and be contacted by a member of our team:

代表Invivyd投資者的訴訟已經在美國馬薩諸塞州地區法院開始。這起訴訟是代表2021年11月29日至2021年12月14日期間(包括首尾兩天)購買Adagio普通股的所有買家。點擊下面的鏈接獲取更多資訊,並與我們團隊的一名成員聯繫:

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

或聯繫約瑟夫·E·利維,Esq.通過電子郵件jlevi@levikorsinsky.com或電話(212)363-7500。對你來說沒有任何費用或義務。

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. NEWS - IVVD NEWS

Invivyd,Inc.f/k/a Adagio治療公司新聞-IVVD新聞

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

案例詳情:起訴書稱,被告做出虛假陳述和/或隱瞞:(A)被告用來聲稱針對新冠肺炎的研究性單抗治療藥物ADG20對奧密克戎有效的表位映射、結構研究和序列分析不充分、不可靠,也不足以聲稱ADG20對奧密克戎有效;(B)被告關於ADG20對奧密克戎有效的說法缺乏合理的事實依據;以及(C)ADG20對奧密克戎變體的有效性是其對先前變體的有效性的300多倍。

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Invivyd during the relevant timeframe, you have until April 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

這對股東意味著什麼:如果您在相關時間段內在Invivyd遭遇損失,您必須在2023年4月3日請求法院指定你為主要原告。你有能力分享任何賠償,並不需要你擔任主要原告。

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

您無需支付任何費用:如果你是班級成員,你可能有權獲得補償,而無需支付任何自掏腰包的成本或費用。與我們的法律團隊討論您的權利,無需支付費用或義務。

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form or call 212-363-7500 to discuss the case.

保護您的財務利益:填寫這份簡短的提交表格或致電212-363-7500討論此案例。

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

為什麼是Levi&Korsinsky:在過去20年裡,Levi&Korsinsky的團隊為憤憤不平的股東爭取了數億美元,並建立了贏得高風險案件的記錄。我們公司擁有在複雜的證券訴訟中代表投資者的廣泛專業知識,並擁有一支70多名員工的團隊為我們的客戶服務。連續七年,Levi&Korsinsky在ISS證券集體訴訟服務公司的前50名報告中被列為美國最大的證券訴訟公司之一。

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

聯繫方式:
Levi&Korsinsky,LLP
約瑟夫·E·利維,Esq.
埃德·科辛斯基,Esq.
百老匯55號,10樓
紐約州紐約市,郵編:10006
郵箱:jlevi@levikorsinsky.com
電話:(212)363-7500
傳真:(212)363-7171

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論